cAMP Signaling and Muscle Adaptations

University of Copenhagen

Status: Unknown

Conditions: Muscle Hypertrophy in Healthy Young Men

Treatments: Other: No training; Drug: Clenbuterol; Drug: Terbutaline; Drug: Placebo; Other: Endurance training; Other: Resistance Training

Study type: Interventional

Funder types: Other

Identifiers

NCT02557581

TUD

Details and patient eligibility

About

The role of cAMP signaling mediated by beta2-adrenergic stimulation with agonists has been well-studied in skeletal muscles of animals. Studies in humans are scant and the scope of the present study is thus to investigate the role of cAMP signaling by beta2-adrenergic stimulation for muscle adaptations in humans.

Enrollment: 72 estimated patients

Sex: Male

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy young men
• 18-35 years of age
• Informed consent
• Active 2-5 hours of training pr. week
• Maximal oxygen uptake (ml/min/kg) of 40-60
• Lean body mass of 55-65 kg / Lean mass index 14-22 kg/m2

Exclusion criteria

• Smoker
• Allergy towards study drugs
• Chronic disease

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

72 participants in 3 patient groups, including a placebo group

Terbutaline

Experimental group

Description:

Beta2-adrenergic stimulation with terbutaline

Treatment:

Other: No training

Other: Endurance training

Other: Resistance Training

Drug: Terbutaline

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Other: No training

Other: Endurance training

Other: Resistance Training

Drug: Placebo

Clenbuterol

Experimental group

Description:

Beta2-adrenergic stimulation with clenbuterol

Treatment:

Other: No training

Drug: Clenbuterol